Zusammenfassung
GRUNDLAGEN: Barrett's Ösophagus (BE) ist die morphologische Komplikation der gastroösophagealen Refluxkkrankheit (GERD) und der wichtigste Risikofaktor für die Entstehung des Adenokarzinoms der Speiseröhre. Die Assoziation zwischen BE und GERD lässt hierbei eine bedeutsame Rolle der ösophagealen Säureexposition vermuten. METHODIK: Übersicht über Protonenpumpenhemmer (PPI)-Therapie bei BE. ERGEBNISSE: Die Onkogenese des Adenokarzinoms von BE über intraepitheliale Neoplasia (Dysplasie) wird noch immer nicht ganz verstanden, aber vermehrte und gestörte Proliferation dürften ein wichtige Faktoren sein. Ex vivo-Experimente und klinische Studie zeigten eine antiproliferative Wirkung der effizienten Säurehemmung auf die intestinale Metaplasia (BE) sowie eine tendenzielle Abnahme der Dysplasieentstehung. Heute werden PPIs erfolgreich im Management der GERD-Symptome eingesetzt, während sie alleine oder im Rahmen eines multimodalen Konzeptes (+endoskopischer Therapie) vielversprechende Therapieansätze erwarten lassen. Dass derzeit eine onkoprotektive Wirkung der PPIs nicht sicher nachgewiesen werden kann, hat möglicherweise auch damit zu tun, dass derzeit viele Patienten eine zu geringe PPI-Dosis erhalten. Da viele Patienten lebenslänglich PPIs benötigen, muss man ihre Nebenwirkungen berücksichtigen und ihren Stellenwert im Vergleich zur chirurgischen Therapie (Fundoplikatio) auswägen. SCHLUSSFOLGERUNGEN: Durch potentiell dauerhafte säurehemmende Wirkung mögen den PPIs eine wichtige Rolle im Langzeit-Management von BE und Ösophaguskarzinom zukommen.
Summary
BACKGROUND: Barrett's esophagus (BE), a significant complication of gastro-esophageal reflux disease (GERD), is the single most important risk factor for esophageal adenocarcinoma. The strong association between BE and chronic GERD suggests that abnormal esophageal acid exposure plays a vital role in this condition. METHODS: Review on PPI treatment for Barrett's esophagus. RESULTS: The progression of BE from specialized intestinal metaplasia to dysplasia and finally invasive carcinoma is incompletely understood, but increased and disordered proliferation is a key cellular event. In both ex vivo experiments and clinical trials in humans, effective acid suppression scales down the proliferative activity of Barrett's metaplasia and the likelihood of dysplasia as well. Today, proton pump inhibitors (PPIs) are almost universally used for the management of reflux symptoms in patients with BE while they may offer many other benefits when used as single agents or in conjunction with pharmacologic or endoscopic therapies. Yet, acid suppression with these drugs may be suboptimal in many patients and their ultimate role in preventing cancer formation has not yet been proven. Because PPIs are life-long therapy for patients with BE, their potential drawbacks need to be reviewed and their relative value need to be balanced when compared to laparoscopic fundoplication. CONCLUSIONS: The ability of PPIs to suppress acid profoundly and consistently may be crucial in the long-term management of BE and esophageal cancer chemoprevention.
References
Spechler S, Goyal R (1996) The columnar-lined esophagus, intestinal metaplasia and Norman Barrett. Gastroenterology 110: 614–621
Barrett NR (1950) Chronic peptic ulcer of the oesophagus and "oesophagitis". Br J Surg 38: 175–182
Triadafilopoulos G (2001) Acid and bile reflux in Barrett's esophagus: a tale of two evils. (Editorial). Gastroenterology 121: 1502–1506
Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE (2006) Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 4: 566–572
Pera M, Cameron AJ, Trastek VF, et al. (1993) Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 104: 510–513
Blot WJ, Devesa SS, Kneller RW, et al. (1991) Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265: 1287–1289
Fass R, Sampliner RE (2003) Barrett's oesophagus: optimal strategies for prevention and treatment. Drugs 63: 555–564
Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G (1999) Differentiation and proliferation Barrett's esophagus and the effects of acid suppression. Gastroenterology 117: 327–333
Fitzgerald RC, Lascar R, Triadafilopoulos G (2001) Review article: Barrett's esophagus, dysplasia and pharmacologic acid suppression. Aliment Pharmacol Ther 15: 269–276
El-Serag HB, Aguirre T, Kuebeler M, Sampliner RE (2004) The length of newly diagnosed Barrett's oesophagus and prior use of acid suppressive therapy. Aliment Pharmacol Ther 19: 1255–1260
Shapiro M, Green C, Faybush EM, Esquivel RF, Fass R (2006) The extent of esophageal acid exposure overlaps among the different gastro-oesophageal reflux disease groups. Aliment Pharmacol Ther 23: 321–329
Spechler SJ (1996) Barrett's esophagus. Semin Gastrointest Dis 7: 51–60
Ouatu-Lascar R, Triadafilopoulos G (1998) Complete elimination of reflux symptoms does not guarantee normalization of intra-esophageal acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 93: 711–716
Katzka DA, Castell DO (1994) Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 89: 989–991
Spechler SJ, Sharma P, Traxler B, Levine D, Falk GW (2006) Gastric and esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: a randomized, double-blind, crossover trial. Am J Gastroenterol 101: 1964–1971
Ortiz A, Martínez de Haro LF, Parrilla P, Molina J, Bermejo J, Munitiz V (1999) 24-h pH monitoring is necessary to assess acid reflux suppression in patients with Barrett's esophagus undergoing treatment with proton pump inhibitors. Br J Surg 86: 1472–1474
Fitzgerald RC (2005) Barrett's oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation? Gut 54 (Suppl 1): 21–26
Solaymani-Dodaran M, Logan RF, West J, Card T, Coupland C (2004) Risk of esophageal cancer in Barrett's esophagus and gastro-esophageal reflux. Gut 53: 1070–1074
Johnson D, Winters C, Spurling T et al (1987) Esophageal acid sensitivity in Barrett's esophagus. J Clin Gastroenterol 9: 23–27
Kuo B, Castell DO (1996) Optimal dosing of omeprazole 40 mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol 91: 1532–1538
Fitzgerald RC, Omary MB, Triadafilopoulos G (1996) Dynamic effects of acid on Barrett's esophagus: an ex vivo proliferation and differentiation model. J Clin Invest 98: 2120–2128
Castell DO, Katzka DA (1999) Importance of adequate acid suppression in the management of Barrett's esophagus. Gastroenterology 117: 1509–1510
Wurm P, de Caestecker J (2003) Pharmacotherapy for chronic gastro-oesophageal reflux disease and Barrett's esophagus. Expert Opin Pharmacother 4: 1049–1061
Cooper BT, Chapman W, Neumann CS, Gearty JC (2006) Continuous treatment of Barrett's esophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence. Aliment Pharmacol Ther 23: 727–733
Basu KK, Bale R, West KP, de Caestecker JS (2002) Persistent acid reflux and symptoms in patients with Barrett's oesophagus on proton-pump inhibitor therapy. Eur J Gastroenterol Hepatol 14: 1187–1192
Fass R, Sampliner RE, Malagon IB, Hayden CW, Camargo L, Wendel CS, Garewal HS (2000) Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor. Aliment Pharmacol Ther 14: 597–602
Gerson LB, Boparai V, Ullah N, Triadafilopoulos G (2004) Esophageal and gastric pH profiles in patients with gastro-esophageal reflux disease and Barrett's esophagus treated with proton pump inhibitors. Aliment Pharmacol Ther 20: 637–643
Wani S, Sampliner RE, Weston AP, Mathur S, Hall M, Higbee A, Sharma P (2005) Lack of predictors of normalization of esophageal acid exposure in Barrett's esophagus. Aliment Pharmacol Ther 22: 627–633
Gerson LB, Shetler K, Triadafilopoulos G (2005) Control of intra-esophageal and intra-gastric pH with proton pump inhibitors in patients with Barrett's esophagus. Dig Liver Dis 37: 651–658
Srinivasan R, Katz PO, Ramakrishnan A, Katzka DA, Vela MF, Castell DO (2001) Maximal acid reflux control for Barrett's oesophagus: feasible and effective. Aliment Pharmacol Ther 15: 519–524
Triadafilopoulos G (2005) Endotherapy for GERD: Angels and demons. Gastrointest Endosc 61: 668–670
Triadafilopoulos G (2004) GERD: the potential for endoscopic intervention. Dig Dis 22: 181–188
Vaezi MF, Singh S, Richter JE (1995) Role of acid and duodenogastric reflux in esophageal mucosal injury: a review of animal and human studies. Gastroenterology 108: 1897–1907
Champion G, Richter JE, Vaezi MF, et al (1994) Duodeno-gastro-esophageal reflux: relationship to pH and importance to Barrett's esophagus. Gastroenterology 107: 747–754
Lundell L, Miettinen P, Myrvold HE, Pedersen SA, Liedman B, Hatlebakk JG, Julkonen R, Levander K, Carlsson J, Lamm M, Wiklund I (2001) Continued (5-year) follow-up of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg 192: 172–181
Yau P, Watson DI, Devitt PG, Game PA, Jamieson GG (2000) Laparoscopic antireflux surgery in the treatment of gastroesophageal reflux in patients with Barrett esophagus. Arch Surg 135: 801–805
Hofstetter WL, Peters JH, DeMeester TR, Hagen JA, DeMeester SR, Crookes PF, Tsai P, Banki F, Bremner CG (2001) Long-term outcome of antireflux surgery in patients with Barrett's esophagus. Ann Surg 234: 532–539
Csendes A, Braghetto I, Burdiles P, Puente G, Korn O, Diaz JC, Maluenda F (1998) Long-term results of classic antireflux surgery in 152 patients with Barrett's esophagus: clinical, radiologic, endoscopic, manometric, and acid reflux test analysis before and late after operation. Surgery 123: 645–657
Jankowski JA, Anderson M (2004) Review article: management of esophageal adenocarcinoma – control of acid, bile and inflammation in intervention strategies for Barrett's esophagus. Aliment Pharmacol Ther 20 (Suppl 5): 71–80
Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC (2004) Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's esophagus. Med J Aust 180: 387–391
El-Serag HB, Aguirre TV, Davis S, Kuebeler M, Bhattacharyya A, Sampliner RE (2004) Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 99: 1877–1883
Overholt BF (2000–2001) Acid suppression and reepithelialization after ablation of Barrett's esophagus. Dig Dis 18: 232–239
DeMeester SR, DeMeester TR (2000) Columnar mucosa and intestinal metaplasia of the esophagus: fifty years of controversy. Ann Surg 231: 303–321
Chang EY, Morris CD, Seltman AK, O'rourke RW, Chan BK, Hunter JG, Jobe BA (2007) The effect of antireflux surgery on esophageal carcinogenesis in patients with Barrett's esophagus: a systematic review. Ann Surg 246: 11–21
Triadafilopoulos G, Kaur B, Sood S, Traxler B, Levine D, Weston A (2006) Effects of esomeprazole combined with aspirin or rofecoxib on prostaglandin E2 production in patients with Barrett's esophagus. Aliment Pharmacol Ther 23: 997–1005
Leedham S, Jankowski J (2007) The evidence base of proton pump inhibitor chemopreventative agents in Barrett's esophagus – the good, the bad, and the flawed. Am J Gastroenterol 102: 21–23
Laine L, Ahnen D, McClain C, Solcia E, Walsh JH (2000) Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 14: 651–668
Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB (2004) Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 292: 1955–1960
Williams C (2001) Occurrence and significance of gastric colonization during acid-inhibitory therapy. Best Pract Res Clin Gastroenterol 15: 511–521
Gurian L, Ward TT, Katon RM (1982) Possible food-borne transmission in a case of pseudomembranous colitis due to Clostridium difficile: influence of gastrointestinal secretions on Clostridium difficile infection. Gastroenterology 83: 465–469
Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296: 2947–2953
Raj A, Jankowski J (2004) Acid suppression and chemoprevention in Barrett's oesophagus. Dig Dis 22: 171–180
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Triadafilopoulos, G. Proton pump inhibitors in Barrett's esophagus: Pluripotent but controversial. Eur Surg 40, 58–65 (2008). https://doi.org/10.1007/s10353-008-0394-0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10353-008-0394-0
Schlüsselwörter
- Protonenpumpenhemmer
- Gastroösophageale Refluxkrankheit
- Barrett's Ösophagus
- Adenokarzinom
- Dysplasie
- Intraepitheliale Neoplasie
- pH-Metrie